GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » Shares Outstanding (EOP)

Nymox Pharmaceutical (Nymox Pharmaceutical) Shares Outstanding (EOP) : 93.27 Mil (As of Sep. 2023)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical Shares Outstanding (EOP)?

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Nymox Pharmaceutical's shares outstanding for the quarter that ended in Sep. 2023 was 93.27 Mil.

Nymox Pharmaceutical's quarterly shares outstanding increased from Jun. 2023 (91.27 Mil) to Sep. 2023 (93.27 Mil). It means Nymox Pharmaceutical issued new shares from Jun. 2023 to Sep. 2023 .

Nymox Pharmaceutical's annual shares outstanding increased from Dec. 2021 (85.55 Mil) to Dec. 2022 (90.52 Mil). It means Nymox Pharmaceutical issued new shares from Dec. 2021 to Dec. 2022 .


Nymox Pharmaceutical Shares Outstanding (EOP) Historical Data

The historical data trend for Nymox Pharmaceutical's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nymox Pharmaceutical Shares Outstanding (EOP) Chart

Nymox Pharmaceutical Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 64.68 71.22 77.96 85.55 90.52

Nymox Pharmaceutical Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 91.27 90.52 90.52 91.27 93.27

Competitive Comparison of Nymox Pharmaceutical's Shares Outstanding (EOP)

For the Biotechnology subindustry, Nymox Pharmaceutical's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical's Shares Outstanding (EOP) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nymox Pharmaceutical's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Nymox Pharmaceutical's Shares Outstanding (EOP) falls into.



Nymox Pharmaceutical Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.


Nymox Pharmaceutical  (OTCPK:NYMXF) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Nymox Pharmaceutical Shares Outstanding (EOP) Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

NYMOX Appeals Deficiency Letter

By Stock market mentor Stock market mentor 01-06-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

NYMOX Provides Current Update

By Marketwired Marketwired 10-11-2021

NYMOX Announces New Marketing Submission for NYMOZARFEX� for BPH

By Value_Insider Value_Insider 12-05-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 05-23-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-02-2022

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

By GlobeNewswire GlobeNewswire 02-15-2023

NYMOX Update

By Marketwired 07-07-2023